Evaluating the osteogenic potential of insulin-like growth factor-1 microspheres on osteoblastic activity around dental implants in patients with type 2 diabetes mellitus using bone scintigraphy: A split-mouth randomized controlled trial

What Was Tested

Researchers studied IGF-1 LR3 in this randomized controlled trial publication.

The Shapiro-Wilks test was used to analyze the normality of data, followed by the independent t test to compare the experimental and placebo groups.

Why It Was Studied

Dental implants are susceptible to early failure when placed in patients diagnosed with type 2 diabetes mellitus.

The osteoinductive potential of insulin-like growth factor-1 (IGF-1) has been widely investigated in animals with type 2 diabetes mellitus, but studies investigating the osteoinductive potential of IGF-1 around dental implants in patients diagnosed with type 2 diabetes mellitus are lacking.

Who Took Part

According to the abstract, 10 participants were involved.

A split-mouth, randomized controlled trial was conducted in 10 participants diagnosed with type 2 diabetes mellitus and with bilaterally missing mandibular posterior teeth.

The 20 sites were randomly allotted to receive the PLGA encapsulated IGF-1 or placebo microspheres followed by the placement of Ø3.8×11-mm implants.

How the Study Was Run

In design terms this was a randomized and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got IGF-1 LR3 and who got the comparison, which limits bias.

A placebo (an inactive look-alike) gave the IGF-1 LR3 group a baseline to be compared against.

Osteoblastic activity was quantitatively assessed with bone scintigraphy scanning on the thirtieth, sixtieth, and 90th day after implant placement.

Intragroup comparison was performed by using repeated-measures ANOVA and the post hoc Bonferroni test (α=.05).

What Was Measured

The subject headings attached to it are Dental Implants, Diabetes Mellitus, Type 2, Insulin-Like Growth Factor I, Microspheres and Mouth.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of IGF-1 LR3 in 10 participants.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 2 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2023 (The Journal of prosthetic dentistry), a journal based in United States.

More context: the IGF-1 LR3 compound page, all human trials.